Table 3.

Results: univariate analysis.

	Overall (n = 551)	No RUX (n = 274)	No or lost response to RUX (n = 104)	RUX (response) (n = 91)	p = value
Non-relapse mortality (at 1 year)	21.9% (95% CI: 18–25)	22.9% (95% CI: 18–28)	25.5% (95% CI: 17–34)	14.8% (95% CI: 7–22)	0.16
Median days to neutrophil engraftment (range)	17 (5–83)	17 (7–57)	17 (10–81))	17 (5–83)	0.43
Acute GVHD II–IV	28.9% (95% CI: 25.1–32.8)	28.9% (95% CI: 23.4–34.4)	27.5% (95% CI: 18.8–36.1)	27.0% (95% CI: 17.7–36.2)	0.92
Chronic GVHD (at 2 years)	46.7% (95% CI: 42.2–51.2)	41.7% (95% CI: 35.4–48.0)	55.7% (95% CI: 45.2–66.2)	50.7% (95% CI: 40.0–61.3)	0.11
Chronic GVHD extensive disease	29.2% (95% CI: 24.7–33.6)	25.5% (95% CI: 19.8–31.1)	37.9% (95% CI: 27.5–48.3)	30.6% (95% CI: 20.8–40.4)	0.08
Overall survival at 2 years	63.2% (95% CI: 59.1–67.2)	60.8% (95% CI: 55.0–66.6)	57.5% (95% CI: 48.0–67.1)	70.0% (95% CI: 60.5–79.5)	0.15
Relapse at 2 years	16.3% (95% CI: 13.2–19.5)	19.1% (95% CI: 14.3–23.9)	15.7% (95% CI: 8.6–22.7)	8.1% (95% CI: 2.3–13.8)	0.05
Event-free survival at 2 years	56.5% (95% CI: 52.3–60.8)	53.7% (95% CI: 47.7–59.8)	49.9% (95% CI: 40.2–59.6)	68.9% (95% CI: 59.2–78.7)	0.01